When will CorMedix report its financial results?

CorMedix Inc. will report its financial results for the third quarter of 2024 before the market opens on October 30, 2024.

What is the name of CorMedix's lead product and when was it approved by the FDA?

The lead product of CorMedix is DefenCath, which was approved by the FDA on November 15, 2023.

Where can investors find more information about CorMedix?

To learn more about CorMedix, one can visit their official website at www.cormedix.com.

CorMedix Inc. to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on October 30, 2024

Q: What time is the corporate update conference call scheduled for?

CorMedix will host a corporate update conference call at 8:30 AM Eastern Time on October 30, 2024.

10/23/24 8:30:00 AM ET

$CRMD

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CRMD alert in real time by email

BERKELEY HEIGHTS, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the third quarter ended September 30, 2024, before the market opens on Wednesday, October 30, 2024, and will host a corporate update conference call at 8:30am Eastern Time.

*Wednesday, October 30*^th @ 8:30am EDT
Domestic:	1-844-481-2557
International:	1-412-317-0561
Webcast:	Webcast Link

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin), which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.

Investor Contact:

Dan Ferry

Managing Director

LifeSci Advisors

[email protected]

(617) 430-7576

Get the next $CRMD alert in real time by email

Date	Price Target	Rating	Analyst
8/26/2024	$13.00	Buy	Rodman & Renshaw
8/10/2023	$6.00	Outperform	RBC Capital Mkts

Date

Price Target

Rating

Analyst

8/26/2024

$13.00

Buy

Rodman & Renshaw

8/10/2023

$6.00

Outperform

RBC Capital Mkts

CorMedix Inc. to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on October 30, 2024

Chat with this insight

Q&A

When will CorMedix report its financial results?

What time is the corporate update conference call scheduled for?

What is the name of CorMedix's lead product and when was it approved by the FDA?

When did CorMedix launch DefenCath in different patient settings?

Where can investors find more information about CorMedix?

Recent Analyst Ratings for $CRMD

$CRMD Press Releases

Fastest customizable press release news feed in the world

CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium

CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update

CorMedix Inc. Announces New Data at ASN Kidney Week 2024

$CRMD Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Todisco Joseph bought $50,718 worth of shares (13,561 units at $3.74), increasing direct ownership by 4% to 352,839 units (SEC Form 4)

Dunton Alan W bought $20,250 worth of shares (6,000 units at $3.38), increasing direct ownership by 65% to 15,250 units (SEC Form 4)

Mistry Erin bought $4,000 worth of shares (1,000 units at $4.00), increasing direct ownership by 26% to 4,900 units (SEC Form 4)

$CRMD Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by CorMedix Inc.

SEC Form SC 13G/A filed by CorMedix Inc. (Amendment)

SEC Form SC 13G filed by CorMedix Inc.

$CRMD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP Hurlburt Elizabeth exercised 140,027 shares at a strike of $4.48 and sold $1,565,670 worth of shares (140,027 units at $11.18), increasing direct ownership by 308% to 185,424 units (SEC Form 4)

Todisco Joseph covered exercise/tax liability with 26,982 shares, decreasing direct ownership by 8% to 325,857 units (SEC Form 4)

SEC Form 4 filed by Lefkowitz Steven W

$CRMD Leadership Updates

Live Leadership Updates

CorMedix Inc. Announces Appointment of Chief Legal Officer

CorMedix Inc. Announces Partnership With The Leapfrog Group

Cormedix Inc. Announces Appointment of Robert A. Stewart to Its Board of Directors

$CRMD Financials

Live finance-specific insights

CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update

CorMedix Inc. to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on October 30, 2024

CorMedix Inc. Reports Second Quarter and Six Month 2024 Financial Results and Provides Business Update

$CRMD SEC Filings

SEC Form 10-Q filed by CorMedix Inc.

CorMedix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form DEF 14A filed by CorMedix Inc.

$CRMD FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

November 17, 2023 - FDA Roundup: November 17, 2023

FDA Approval for DEFENCATH issued to CORMEDIX INC

$CRMD Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Rodman & Renshaw initiated coverage on Cormedix with a new price target

RBC Capital Mkts initiated coverage on Cormedix with a new price target

Needham reiterated coverage on Cormedix with a new price target

$CRMD Market Insights

Live Market Insights

Needham Reiterates Buy on Cormedix, Maintains $10 Price Target

CorMedix Receives FDA Support for Expanded Indication of DefenCath in Adult TPN Patients; Plans to Submit Clinical Protocol in Q3 2024 and Initiate Program by Year-End

CorMedix Announces CMS Grants Pass-Through Status For DefenCath Under Hospital Outpatient Prospective Payment System (OPPS)

Recent Analyst Ratings for
$CRMD

$CRMD
Press Releases

$CRMD
Insider Purchases

$CRMD
Large Ownership Changes

$CRMD
Insider Trading

$CRMD
Leadership Updates

$CRMD
Financials

$CRMD
SEC Filings

$CRMD
FDA approvals

$CRMD
Analyst Ratings

$CRMD
Market Insights